New hope for rare bone cancer: targeted drugs enter early trial
NCT ID NCT07560410
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial will test two targeted drugs, crizotinib and alectinib, in 10 adults with a rare form of bone cancer that has a specific ALK gene change. Participants must have already tried standard treatments or have no standard options left. The goal is to see if these drugs can shrink tumors and control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- crizotinib (Xalkori) or alectinib (Alecensa)
- What this could lead to
- If successful, this could point toward a targeted treatment option for people with this rare bone cancer who have no other options.
- What could go wrong
- This is a very early, small trial with only 10 participants, so results may not apply widely. The drugs may not shrink tumors or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALK-POSITIVE BONE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
Taichung, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive injection target bone tumors? a Dose-Finding trial aims to find out
- New database aims to reduce bone cancer surgery risks
- Hip bone reconstruction after cancer: a 30-Year review
- New knee prosthesis helps bone cancer patients walk again
- New drug shows promise for stubborn cancers
- Sound waves vs. bone pain: can ultrasound replace radiation?